Complement as a target in COVID-19?
Antonio Maria Risitano, Dimitrios C. Mastellos, Markus Stefan Huber-Lang et al. · Nature reviews. Immunology · 2020
Cited by 484 works. doi:10.1038/s41577-020-0320-7 Open-access PDF
Authors
- Antonio Maria Risitano
- Dimitrios C. Mastellos
- Markus Stefan Huber-Lang
- Despina Yancopoulou
- Cecília Garlanda
- Fabio Ciceri
- John D. Lambris
References
- Clinical Characteristics of Coronavirus Disease 2019 in China
- Coronavirus infections and immune responses
- Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
- Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation
- Clinical promise of next-generation complement therapeutics
- Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndrome